Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Fig. 4

Overall survival (OS) from diagnosis of metastatic disease (a), OS from T-DM1 start (b) and progression free survival to the second-line of treatment (PFS2) (c), in patients treated with trastuzumab-based first-line and T-DM1 in second-line (T - > T-DM1) and in patients treated with pertuzumab-trastuzumab-based first-line and T-DM1 in second-line (P + T - > T-DM1)

Back to article page